This is one of the most ambitious pharmaceutical discovery opportunities of our lifetime. It’s not hype. The wealth of blockbuster targets and the sheer scope of what MYCO is playing with leave nearly every other biotech or pharma startup on my screen in the shade.
It’s all about Fungi. People have sought out various species since ancient times. Off the top of my head I can point to shiitake, cordyceps, reishi and on and on. There are whole medical journals dedicated to this stuff.
But here’s the thing. Some of the most promising compounds have been legally forbidden fruit for generations. Banned in 1968, only decriminalized in Denver last year. Now that the FDA and DEA are loosening up on clinical research, legitimate developers like MYCO can finally figure out what the science behind what these molecules actually do and how to refine them into reliable prescription medicines.
Think of how far pharmacology has come in the last 60+ years while this mushroom was off limits even in the lab. Back then, now standard techniques like chromatography and protein synthesis were barely getting started. Nobody got a chance to deploy them before the wall went up.
DNA science was in its infancy. Antiviral drugs and modern vaccines were the hottest things around. Biotech as we know it was still hypothetical stuff. As all these incredibly powerful discovery tools built the Big Pharma empires of today, the most magic of all mushrooms remained untouched.
Everyone knew these compounds have a chemical effect on the nervous system. It’s why they were banned in the first place. But until science fills the gap, we don’t really know how many medical conditions can be treated with modern derivatives. In theory, MYCO can indeed rock the world to the foundations and build it up from there.
You might be familiar with formal research on another forbidden food, a plant (distinctive green leaves, funky odor, mood-altering smoke) that has already sown the seeds of a $4 billion company. That’s what GW Pharmaceuticals, the first and only prescription CBD therapy with FDA approval, is worth now.
And that drug “only” brings in about $600 million a year in sales. Small stakes in pharma terms . . . but it just shows what Wall Street will pay when you have a head start on a green field opportunity. Other people are trying to catch up to GW Pharma, but until they do, that company has the whole commercial space all to itself.
Of course GW Pharma is already $4 billion into its journey. Shareholders have already reaped big rewards for their insight, conviction and raw perseverance in long stretches when the market said CBD and the FDA would never mix.
MYCO, on the other hand, is still fresh. With 137 million shares available (as of the last annual report released June 2), we’re still only looking at maybe a $60 million enterprise at this stage. Tiny in a world of Big Pharma behemoths.
Most of the adventure here is in the future . . . after all, this company has really only existed in its current form since June 6. Baby steps, bonanza potential.
SECRET ORIGINS OF A STEALTH STOCK
Before June 6, the company that would become MYCO had a robust and expansive presence in medicinal and recreational products markets: enhanced water, botanical tea, cultivation, clinical research. There are a lot of moving parts on that side and more coming all the time.
Listing them all at this point would only bog down this discussion because, let’s face it, while the “green” revolution is generating plenty of cash for people in the right spots, you already have plenty of companies to choose from there. In fact MYCO has hired from some of the giants you probably know . . . industry legends like Ebbo, giants like Canopy Growth Corp.
The executive summary is that management knows how the business of what they call “naturally sourced therapies” works. They’re enthusiastic and even aggressive when it comes to putting together the platform they need to stay ahead of the giants. And that’s given them a broad base of assets and expertise to work with as they hunt the magic mushroom prize.
A few of MYCO’s established brands.
Reading between the lines, MYCO might have even been content to stay focused on its existing operations before the opportunity to leap to leadership in the mushroom space showed up. The letter of intent was signed April 7. The definitive deal followed 3 weeks later.
Just 3 weeks after that, a plan to change the name of the whole company to align with the mushroom message was already on the table. The board approved it. They move FAST. Here we are now: a new world.
Maybe you missed a few of these developments because the corona crisis and what’s been going on in the market around that consumed your attention. I don’t blame you. A lot of people missed out on what was going on inside MYCO over the last few months. Or if they saw the headlines, they didn’t put it all together.
That’s all right. Now’s our chance to catch up with what’s been going on here behind the scenes and get this little stock on screen before everyone else.
MY MEDICINE, MY MYCOLOGY
MYCO uses the word “fungtional” to describe its approach to mushrooms in particular. It’s a combination of fungus and functional, as in “functional food.” Functional food is a bona fide global phenomenon . . . 436 MILLION organic search hits. According to the one from the Mayo Clinic, it’s really just things people eat that have positive health impacts.
That can mean vitamins, nutriceuticals, antioxidants, all those “traditional herbal benefits” that drove mushroom medicine for centuries. Plants and fungi provide chemicals that increase the body’s performance. Eat the right things and you’re on the right track.
But until someone steps up with the clinical trials, you’re really just “self medicating,” even in places where those foods are legal. So you need someone like MYCO with the willpower to accelerate the development path and the vision to avoid the pitfalls.
First thing MYCO did in this space was start building out a dedicated 7,500 square foot mycology research lab in Denver. They moved into it a few weeks ago. The space is configured for FDA-compliant food testing so it’s ready for Big Science . . . Dr. Mali Reddy is on the team and he’s already been nominated for seven Nobel prizes.
Rob Roscow is the chief scientific officer. You might have heard of him as the guy who ran the world’s first cannabinoid gene lab for Ebbu, which got bought out for $330 million (CAN$ 429 million) a few years ago. It’s a blue-ribbon pedigree in the alternative chemistry world.
He built a new field of genomic research at Ebbu. After that, he got deep into mushroom science. MYCO’s Chief Operating Officer Damon Michaels calls him an incredible geneticist, compares him to Isaac Newton and Nikola Tesla.
For our purposes, the detail that matters is that he knows how to take a forgotten plant into the modern world of chemical assays and genomic maps, plugging previously unknown molecules into all those drug discovery models that smart people have created since the mid-1960s.
And his reputation has earned him fans in key places like the University of Alberta’s pharmaceutical research institute, one of the top drug development centers on the planet. MYCO will be working with them to see how to tap the fungus pharma universe most effectively.
It’s an elite partnership that would be hard for would-be competitors to duplicate . . . genius recognizes genius and ignores everyone else. As the dean of the pharma school says, there are already plenty of “novel molecule leads for unique mycological medications” on their radar. I suspect we’re going to see a LOT of news come out of this relationship over the next few years.
A COMMANDING HEAD START
I can’t talk about this University of Alberta angle enough. For one thing, that school has an extremely rare license to deal with Schedule 1 substances. That means import, export, R&D and manufacturing, all the way up to commercial scale.
You need that kind of capability if you want to run clinical trials, much less one day take your discoveries to the mass market. And the university doesn’t open its doors to everybody who comes in off the street. They’re extremely choosy.
Even if someone else were to talk the university into a similar mushroom research deal, it could easily take 6-12 months for the negotiations and due diligence. By that point, who knows how far ahead MYCO will be?
Remember, billions of dollars are won and lost in Big Pharma depending on who moves through the clinical trials fastest and hits the FDA first. When you’re the only drug on the market that works, you get first pick of patient prescriptions. When you’re No. 2, you get scraps at best.
We might not see MYCO reach the FDA review stage for a few years. This will be the kind of story that requires patience. But whenever MYCO hits the finish line, I have a feeling the runners-up will still be 6-12 months behind . . . even if they have the University of Alberta on their side. Drug development isn’t about instant gratification as much as simply getting there first. Just ask GW Pharma shareholders!
So what targets will MYCO chase? The FDA is relatively open toward mushroom antidepressants, even handing out a coveted fast-track breakthrough designation a few years back. If that program fizzles, there’s room for someone else to try again. And even if it succeeds, it opens the door wide to every other mood therapy we can imagine.
One type of mushroom inhibits serotonin uptake in the brain. Another whole genus makes the mood chemical organically. Pain relief, sleep, anxiety . . . even Alzheimer’s, an enormous and crucial development target Big Pharma has chased without success.
MYCO isn’t just playing with one mushroom. It has the entire fungal kingdom (144,000 species, give or take) on its radar and the artificial intelligence lab of the University of Alberta to screen the prospects fast and efficiently.
You know penicillin came out of a mold. That’s a fungus. MYCO can hunt a whole new generation of antibiotics ($45 billion now) and antiviral drugs ($70 billion by mid-decade, thanks to corona and friends). Finding even one new winner in that garden of 144,000 species can be big enough to birth not just a company but a whole industry, a way of doing medicine.
That’s the kind of opportunity MYCO is looking at. After all, GW Pharma’s drug only targets a rare form of epilepsy, but that $600 million sales cycle translates into $4 billion for shareholders.
What if MYCO hits even ONE of those blockbuster balls down here at $60 million in market cap today? And then what if they hit it AGAIN?
Remember, I’ve barely talked about the legacy business. MYCO has what it takes to deliver its discoveries via vape pens, soft gel capsules, tea, bottled water and other beverages.
Existing cultivation facilities in Jamaica can supply the Canadian researchers. Then there’s the Colorado manufacturing lab and distribution is run out of Texas. The company can already reach 30,000 retail outlets like Costco, Kroger and Whole Foods.
Magic plant or magic mushroom, wherever the products come from, this is shaping up to become a full-fledged medical system for tomorrow. MYCO management calls their take on vertical integration “spore-to-sale.” They’ve even copyrighted the phrase.
They dream big and in technicolor. Most of us do that. But they also have the tools and relationships to make the dream come true. That’s what investing is all about, right? Take a little dream, nourish it with time and hard work . . . and rock the world.
This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on MYCOF (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety.
Small Cap Exclusive profiles are not a solicitation or recommendation to buy, sell or hold securities. Small Cap Exclusive is a paid advertiser and is not offering securities for sale. Neither Small Cap Exclusive nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by Small Cap Exclusive its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.
Small Cap Exclusive does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.
Information presented by Small Cap Exclusive may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.
THIS SITE IS PROVIDED BY SMALL CAP EXCLUSIVE ON AN “AS IS” AND “AS AVAILABLE” BASIS. SMALL CAP EXCLUSIVE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.
TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, SMALL CAP EXCLUSIVE DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. SMALL CAP EXCLUSIVE DOES NOT WARRANT THAT THIS SITE, IT’S SERVERS, OR E-MAIL SENT FROM SMALL CAP EXCLUSIVE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. SMALL CAP EXCLUSIVE, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.
CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS.
The website contains links to other related World Wide Web Internet sites and resources. Small Cap Exclusive is not responsible for the availability of these outside resources, or their contents, nor does Small Cap Exclusive endorse nor is Small Cap Exclusive responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall Small Cap Exclusive be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).
We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, Mydecine Innovations Group, Inc. Small Cap Exclusive has been hired by Mydecine Innovations Group, Inc. for a period beginning on June 22, 2020 to publicly disseminate information about (MYCOF) via website and email. We have been compensated $50,000. We will update any changes to our compensation.
Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign. Mydecine Innovations Group, Inc. is a penny stock that was illiquid (little to no trading volume) prior to our Campaign, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.
The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.
All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.
We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.
The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.
We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.
We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.
There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.
We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.
We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.
We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.
We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose my compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.
Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.
The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.
If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.
No securities commission or other regulatory authority in Canada or any other country or jurisdiction has in any way passed upon this information and no representation or warranty is made by to that effect. The information is not a substitute for independent professional advice before making any investment decisions. The CSE (Canadian Securities Exchange) has not reviewed the information in this Article and does not accept responsibility for the adequacy or accuracy of it.